VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Burris on the Impact of the ASCO Annual Meeting

Howard A "Skip" Burris, III, MD
Published: Thursday, May 28, 2015



Howard Burris, III, MD, Giant of Cancer Care in Drug Development, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute, discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.

One of the biggest benefits of ASCO’s annual meeting is the world’s thought-leaders coming together to present, discuss, and debate the latest results and research in cancer, says Burris. However, the ‘hallway conversations’ that happened amongst attendees and presenters off of the podium are just as meaningful. A lot of ideas and collaborations throughout the industry occur this way, he says.

At this year’s conference, Burris is most looking forward to research regarding the harnessing of the immune system to fight cancer. This is an area that has been discussed abstractly for many years, but only recently became a topic in which concrete data was presented at ASCO, says Burris.

<<< View more from the 2015 ASCO Annual Meeting



Howard Burris, III, MD, Giant of Cancer Care in Drug Development, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute, discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.

One of the biggest benefits of ASCO’s annual meeting is the world’s thought-leaders coming together to present, discuss, and debate the latest results and research in cancer, says Burris. However, the ‘hallway conversations’ that happened amongst attendees and presenters off of the podium are just as meaningful. A lot of ideas and collaborations throughout the industry occur this way, he says.

At this year’s conference, Burris is most looking forward to research regarding the harnessing of the immune system to fight cancer. This is an area that has been discussed abstractly for many years, but only recently became a topic in which concrete data was presented at ASCO, says Burris.

<<< View more from the 2015 ASCO Annual Meeting




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x